{ "version": "2.2", "instance": { "azn-20260630x6k.htm": { "nsprefix": "azn", "nsuri": "http://www.astrazeneca.com/20260630", "dts": { "schema": { "local": [ "azn-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "azn-20260630_cal.xml" ] }, "definitionLink": { "local": [ "azn-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "azn-20260630_lab.xml" ] }, "presentationLink": { "local": [ "azn-20260630_pre.xml" ] }, "inline": { "local": [ "azn-20260630x6k.htm" ] } }, "keyStandard": 141, "keyCustom": 89, "axisStandard": 16, "axisCustom": 1, "memberStandard": 19, "memberCustom": 70, "hidden": { "total": 8, "http://xbrl.sec.gov/dei/2025": 8 }, "contextCount": 491, "entityCount": 1, "segmentCount": 89, "elementCount": 399, "unitCount": 8, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 867, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": null, "uniqueAnchor": null }, "R2": { "role": "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome", "longName": "00100 - Statement - Condensed consolidated statement of comprehensive income", "shortName": "Condensed consolidated statement of comprehensive income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "i", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "azn:ProductRevenue", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R3": { "role": "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical", "longName": "00105 - Statement - Condensed consolidated statement of comprehensive income (Parenthetical)", "shortName": "Condensed consolidated statement of comprehensive income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_USD_shares_6ykY6xe83UGKRbW-DZjBaQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_USD_shares_6ykY6xe83UGKRbW-DZjBaQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition", "longName": "00200 - Statement - Condensed consolidated statement of financial position", "shortName": "Condensed consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity", "longName": "00300 - Statement - Condensed consolidated statement of changes in equity", "shortName": "Condensed consolidated statement of changes in equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_EquityAttributableToOwnersOfParentMember_ZKg_Rli9RkmXppBQ3tb7HQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_EquityAttributableToOwnersOfParentMember_ZKg_Rli9RkmXppBQ3tb7HQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows", "longName": "00400 - Statement - Condensed consolidated statement of cash flows", "shortName": "Condensed consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:AdjustmentsForFinanceIncomeCost", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R7": { "role": "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPolicies", "longName": "10101 - Disclosure - Basis of preparation and accounting policies", "shortName": "Basis of preparation and accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.astrazeneca.com/role/DisclosureIntangibleAssets", "longName": "10201 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.astrazeneca.com/role/DisclosureNetDebt", "longName": "10301 - Disclosure - Net debt", "shortName": "Net debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfNetDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfNetDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.astrazeneca.com/role/DisclosureFinancialInstruments", "longName": "10401 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilities", "longName": "10501 - Disclosure - Legal proceedings and contingent liabilities", "shortName": "Legal proceedings and contingent liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026", "longName": "10601 - Disclosure - Product Sales year-on-year analysis: H1 2026", "shortName": "Product Sales year-on-year analysis: H1 2026", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026", "longName": "10701 - Disclosure - Product Sales year-on-year analysis: Q2 2026", "shortName": "Product Sales year-on-year analysis: Q2 2026", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.astrazeneca.com/role/DisclosureAllianceRevenue", "longName": "10801 - Disclosure - Alliance Revenue", "shortName": "Alliance Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfAllianceRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfAllianceRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.astrazeneca.com/role/DisclosureCollaborationRevenue", "longName": "10901 - Disclosure - Collaboration Revenue", "shortName": "Collaboration Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfCollaborationRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfCollaborationRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpense", "longName": "11001 - Disclosure - Other operating income and expense", "shortName": "Other operating income and expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesPolicies", "longName": "20102 - Disclosure - Basis of preparation and accounting policies (Policies)", "shortName": "Basis of preparation and accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.astrazeneca.com/role/DisclosureNetDebtTables", "longName": "30303 - Disclosure - Net debt (Tables)", "shortName": "Net debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:TabularDisclosureOfNetDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfNetDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:TabularDisclosureOfNetDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfNetDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Tables", "longName": "30603 - Disclosure - Product Sales year-on-year analysis: H1 2026 (Tables)", "shortName": "Product Sales year-on-year analysis: H1 2026 (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentHalfYearPeriodYearOnYearTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentHalfYearPeriodYearOnYearTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Tables", "longName": "30703 - Disclosure - Product Sales year-on-year analysis: Q2 2026 (Tables)", "shortName": "Product Sales year-on-year analysis: Q2 2026 (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentPeriodYearOnYearTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentPeriodYearOnYearTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.astrazeneca.com/role/DisclosureAllianceRevenueTables", "longName": "30803 - Disclosure - Alliance Revenue (Tables)", "shortName": "Alliance Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:ScheduleOfAllianceRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfAllianceRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:ScheduleOfAllianceRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfAllianceRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueTables", "longName": "30903 - Disclosure - Collaboration Revenue (Tables)", "shortName": "Collaboration Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfCollaborationRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "azn:DisclosureOfCollaborationRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpenseTables", "longName": "31003 - Disclosure - Other operating income and expense (Tables)", "shortName": "Other operating income and expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails", "longName": "40101 - Disclosure - Basis of preparation and accounting policies (Details)", "shortName": "Basis of preparation and accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "azn:FinancialResourcesThatIncludeCashUndrawnCommittedBankFacilitiesExcludingCurrentOutstandingDebt", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_Xx5TLQyUYEOUjkz9AdlnXg", "name": "azn:FinancialResourcesThatIncludeCashUndrawnCommittedBankFacilitiesExcludingCurrentOutstandingDebt", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "azn:IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails", "longName": "40201 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_IntangibleAssetsUnderDevelopmentMember_aujEqbBFU02s89XqnjJuSQ", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R26": { "role": "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "longName": "40301 - Disclosure - Net debt (Details)", "shortName": "Net debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_12_31_2025_94uYKIOEF0acDi0jMxkKlA", "name": "ifrs-full:LongtermBorrowings", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_t04pxVDwCEC2eN5Pu2ekQg", "name": "azn:CashFlowNonCurrentInstalmentsOfLoans", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "azn:TabularDisclosureOfNetDebtTableTextBlock", "azn:DisclosureOfNetDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R27": { "role": "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails", "longName": "40401 - Disclosure - Financial Instruments (Details)", "shortName": "Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_ifrs-full_BusinessCombinationsAxis_azn_DiabetesAllianceMember_0jqUY-Brl0m0YPIYBqu2ug", "name": "azn:ContingentConsiderationPaymentBusinessCombinationsClassifiedAsInvestingActivities", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R28": { "role": "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails", "longName": "40501 - Disclosure - Legal proceedings and contingent liabilities - Legal proceedings (Details)", "shortName": "Legal proceedings and contingent liabilities - Legal proceedings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_12_31_2025_azn_ClassesOfContingentAssetsAxis_azn_ForxigaPatentProceedingsAustraliaMember_owMdD68090iREYGWCWOzPg", "name": "azn:NumberOfPatentsClaimedToBeInfringed", "unitRef": "Unit_Standard_patent_984kuKt19k2V9gn-0syQ_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_azn_ClassesOfContingentAssetsAxis_azn_ForxigaPatentProceedingsAustraliaMember_owMdD68090iREYGWCWOzPg", "name": "azn:NumberOfPatentsClaimedToBeInfringed", "unitRef": "Unit_Standard_patent_984kuKt19k2V9gn-0syQ_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "longName": "40601 - Disclosure - Product Sales year-on-year analysis: H1 2026 (Details)", "shortName": "Product Sales year-on-year analysis: H1 2026 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "i", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details", "longName": "40701 - Disclosure - Product Sales year-on-year analysis: Q2 2026 (Details)", "shortName": "Product Sales year-on-year analysis: Q2 2026 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "i", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_ProductsAndServicesAxis_azn_InfectiousDiseaseMember_tC3xVwMxHUWqnNjXQ_JcnQ", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "b", "p", "td", "tr", "table", "azn:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentPeriodYearOnYearTableTextBlock", "azn:DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R31": { "role": "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "longName": "40801 - Disclosure - Alliance Revenue (Details)", "shortName": "Alliance Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "azn:AllianceRevenue", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "i", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_ifrs-full_ProductsAndServicesAxis_azn_EnhertuMember_htMn-D6LIEiz2xmeLSyOMQ", "name": "azn:AllianceRevenue", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "azn:ScheduleOfAllianceRevenueTableTextBlock", "azn:DisclosureOfAllianceRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R32": { "role": "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "longName": "40901 - Disclosure - Collaboration Revenue (Details)", "shortName": "Collaboration Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_4_1_2025_To_6_30_2025_EwPOZAXhEEaTYkwSa3iqUg", "name": "azn:CollaborationRevenue", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_ifrs-full_ProductsAndServicesAxis_azn_FarxigaSalesMilestonesMember_81RnM5xrmkOxfMOXKTyxyA", "name": "azn:CollaborationRevenue", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "azn:DisclosureOfCollaborationRevenueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "unique": true } }, "R33": { "role": "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpenseDetails", "longName": "41001 - Disclosure - Other operating income and expense (Details)", "shortName": "Other operating income and expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_io6rqf1eRkylJ0EzS8YQ8w", "name": "ifrs-full:OtherOperatingIncomeExpense", "unitRef": "Unit_Standard_USD_L5Q8BGARSEmGr8_TDx3Nzw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "azn-20260630x6k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r18", "r130" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Diluted weighted average number of Ordinary Shares in issue (millions)" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss", "terseLabel": "Depreciation, amortisation and impairment" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Finance income and expense" } } }, "auth_ref": [ "r252" ] }, "azn_AdjustmentsForLossesGainsOnDisposalOfIntangibleAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "AdjustmentsForLossesGainsOnDisposalOfIntangibleAsset", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for losses (gains) on disposal of intangible assets to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for losses (gains) on disposal of intangible asset", "terseLabel": "Gains on disposal of intangible assets" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of investments accounted for using equity method", "negatedLabel": "Share of after tax losses of associates and joint ventures" } } }, "auth_ref": [ "r252" ] }, "azn_AirsupraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "AirsupraMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Airsupra", "label": "Airsupra [Member]", "terseLabel": "Airsupra" } } }, "auth_ref": [] }, "azn_AllianceRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "AllianceRevenue", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "azn_ProductRevenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The amount of alliance revenue", "label": "Alliance Revenue" } } }, "auth_ref": [] }, "azn_AllianceRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "AllianceRevenueAbstract", "lang": { "en-us": { "role": { "documentation": "Alliance revenue", "label": "Alliance Revenue." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "azn_AmountOfClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "AmountOfClaim", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of the claim filed.", "label": "Amount Of Claim", "terseLabel": "Amount of claim" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r54", "r55", "r56", "r92", "r96", "r149", "r150", "r174" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "azn_BankOverdraftMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BankOverdraftMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bank overdrafts.", "label": "Overdrafts" } } }, "auth_ref": [] }, "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankOverdraftsClassifiedAsCashEquivalents", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Bank overdrafts", "negatedTerseLabel": "Overdrafts" } }, "en": { "role": { "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic earnings per $0.25 Ordinary Share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r9", "r10" ] }, "azn_BasisOfPresentationAndAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BasisOfPresentationAndAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "documentation": "na", "label": "Basis of preparation and accounting policies" } } }, "auth_ref": [] }, "azn_BaxfendyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BaxfendyMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Baxfendy.", "label": "Baxfendy [Member]", "terseLabel": "Baxfendy" } } }, "auth_ref": [] }, "azn_BeyfortusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BeyfortusMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Beyfortus", "label": "Beyfortus [Member]", "terseLabel": "Beyfortus" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails", "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "negatedPeriodEndLabel": "Gross borrowings at end of period", "negatedPeriodStartLabel": "Gross borrowings at beginning of period" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r254" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r254" ] }, "azn_BreztriMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BreztriMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Breztri.", "label": "Breztri", "terseLabel": "Breztri" } } }, "auth_ref": [] }, "azn_BrilintaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "BrilintaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Brilinta.", "label": "Brilinta", "terseLabel": "Brilinta" } } }, "auth_ref": [] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r70", "r138" ] }, "ifrs-full_BusinessCombinationsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r70", "r73", "r138" ] }, "azn_CalquenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CalquenceMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Calquence.", "label": "Calquence", "terseLabel": "Calquence" } } }, "auth_ref": [] }, "azn_CardiovascularRenalAndMetabolismProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CardiovascularRenalAndMetabolismProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cardiovascular, renal and metabolism products.", "label": "BioPharmaceuticals: total CVRM", "terseLabel": "BioPharmaceuticals: total CVRM" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "weight": 1.0, "order": 1.0 }, "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails", "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r35", "r51", "r117", "r167" ] }, "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents if different from statement of financial position", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "totalLabel": "Total Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r253" ] }, "azn_CashAndCashEquivalentsOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashAndCashEquivalentsOtherInvestments", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The total of cash and cash equivalents along with other investments.", "label": "Cash and Cash Equivalents, Other Investments", "periodEndLabel": "Cash and investments at end of period", "periodStartLabel": "Cash and investments at beginning of period" } } }, "auth_ref": [] }, "azn_CashCollateralOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashCollateralOnDerivatives", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash collateral on financial derivatives.", "label": "Cash Collateral on Derivatives", "terseLabel": "Cash collateral on financial derivatives" } } }, "auth_ref": [] }, "azn_CashCollateralOnDerivativesPostedByGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashCollateralOnDerivativesPostedByGroup", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash collateral on financial derivatives by the group.", "label": "Cash Collateral On Derivatives Posted by Group", "terseLabel": "Cash collateral posted by the Group" } } }, "auth_ref": [] }, "azn_CashFlowCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowCashAndInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash and cash equivalents due to cash activity.", "label": "Cash Flow, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowCashAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowCashAndInvestments", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowNetFundsAndBorrowings", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash and investments due to cash activity.", "label": "Cash Flow, Cash and Investments", "totalLabel": "Cash and investments - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowCurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current borrowings due to cash activity.", "label": "Cash Flow Current Borrowings", "negatedLabel": "Current instalments of loans - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowCurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowCurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowing", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in Current borrowings and current portion of non-current borrowing due to cash activity.", "label": "Cash Flow, Current borrowings and current portion of non-current borrowing", "negatedLabel": "Current borrowings and current portion of non-current borrowing - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowCurrentLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowCurrentLeases", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current leases due to cash activity.", "label": "Cash Flow, Current Leases", "negatedLabel": "Current instalments of leases - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowGrossBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowGrossBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowNetBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in gross borrowings due to cash activity.", "label": "Cash Flow, Gross Borrowings", "negatedTotalLabel": "Gross borrowings - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowNetBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowNetBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowNetFundsAndBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net borrowings due to cash activity.", "label": "Cash Flow, Net Borrowings", "negatedTotalLabel": "Net borrowings - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowNetDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowNetDerivativeFinancialInstruments", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowNetBorrowings", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net derivative financial instruments due to cash activity.", "label": "Cash Flow, Net Derivative financial instruments", "terseLabel": "Net derivative financial instruments - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowNetFundsAndBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowNetFundsAndBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net funds and borrowings due to cash activity.", "label": "Cash Flow, Net Funds and Borrowings", "negatedTotalLabel": "Net debt - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowNonCurrentInstalmentsOfLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowNonCurrentInstalmentsOfLoans", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowTotalNonCurrentBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in non-current instalments of loans due to cash activity.", "label": "Cash Flow, Non-Current Instalments of Loans", "negatedLabel": "Non-current instalments of loans - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowOtherInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowOtherInvestmentsCurrent", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowCashAndInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other investments, current due to cash activity.", "label": "Cash Flow, Other Investments, Current", "terseLabel": "Other investments, current - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowTotalCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowTotalCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowGrossBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in total current borrowings due to cash activity.", "label": "Cash Flow, Total current Borrowings", "negatedLabel": "Total current debt - Cash flow" } } }, "auth_ref": [] }, "azn_CashFlowTotalNonCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowTotalNonCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_CashFlowGrossBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in total non-current borrowings due to cash activity.", "label": "Cash Flow, Total Non-current Borrowings", "negatedTotalLabel": "Total long-term debt - Cash flow" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash outflow from financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r27", "r36" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) increase (decrease) in current borrowings", "terseLabel": "Movement in short-term borrowings" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "azn_CashFlowsFromUsedInOperatingAndInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash outflow from investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r27", "r36" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "azn_CashFlowsFromUsedInOperatingAndInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash inflow from operating activities" } } }, "auth_ref": [ "r27", "r36" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "azn_CashFlowsFromUsedInOperatingAndInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CashFlowsFromUsedInOperatingAndInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Net cash flows from (used in) operating and investing activities", "label": "Cash flows from (used in) operating and investing activities", "totalLabel": "Net cash inflow before financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperations", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Cash generated from operations" } }, "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } } }, "auth_ref": [ "r212", "r215" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r86", "r141" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r86", "r141" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in equity", "totalLabel": "Net movement" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r160" ] }, "azn_ClassesOfContingentAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ClassesOfContingentAssetsAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Classes of contingent assets [Axis]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfContingentLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r71", "r129" ] }, "ifrs-full_ClassesOfContingentLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } } }, "auth_ref": [ "r17", "r71" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r69", "r83", "r84", "r104", "r105", "r154" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r69", "r83", "r84", "r104", "r105", "r154" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r83", "r84", "r104", "r105" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r83", "r84", "r104", "r105" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r133" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r21", "r133" ] }, "azn_CollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CollaborationRevenue", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The amount of revenue arising from transactions involving the Company's medicines as well as medicine the Company has acquired an interest in. Such income included upfront consideration, milestones receipts and royalties, as well as other income from collaborations.", "label": "Collaboration Revenue..", "terseLabel": "Collaboration Revenue", "verboseLabel": "Total collaboration revenue" } } }, "auth_ref": [] }, "azn_CollateralReceivedFromDerivativeCounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CollateralReceivedFromDerivativeCounterpartiesMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for collateral received from derivative counterparties", "label": "Collateral received from derivative counterparties [Member]", "terseLabel": "Collateral received from derivative counterparties" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive income for the period" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r38", "r40", "r48", "r125", "r137", "r156", "r186", "r218" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income attributable to [abstract]", "terseLabel": "Total comprehensive income attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r156", "r189" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "terseLabel": "Owners of the Parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r156", "r190" ] }, "azn_ContingentAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ContingentAssetsDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent assets", "label": "Contingent assets [Domain]" } } }, "auth_ref": [] }, "azn_ContingentConsiderationFairValueMovement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ContingentConsiderationFairValueMovement", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustment of contingent consideration due to change in fair value.", "label": "Contingent consideration, fair value movement", "terseLabel": "Fair value movements on contingent consideration arising from business combinations" } } }, "auth_ref": [] }, "azn_ContingentConsiderationPaymentBusinessCombinationsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ContingentConsiderationPaymentBusinessCombinationsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of contingent consideration paid on account of business combinations.", "label": "Contingent consideration payment, business combinations, classified as investing activities", "negatedLabel": "Payment of contingent consideration from business combinations", "terseLabel": "Payment of contingent consideration from business combinations" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "negatedLabel": "Cost of sales" } } }, "auth_ref": [ "r155", "r199" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r87" ] }, "azn_CourtDecisionOnAmountOfMilestoneThatHadBeenReached": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CourtDecisionOnAmountOfMilestoneThatHadBeenReached", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Court decision on amount of milestone that had been reached.", "label": "Court decision on amount of milestone that had been reached", "terseLabel": "Court decision on amount of milestone that had been reached" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "azn_CrestorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CrestorMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Crestor.", "label": "Crestor", "terseLabel": "Crestor" } } }, "auth_ref": [] }, "azn_CrestorSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CrestorSalesMilestonesMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Crestor, sales milestones.", "label": "Crestor, sales milestones [Member]", "terseLabel": "Crestor: sales milestones" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r44", "r178", "r218" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "azn_CurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "CurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current borrowings which may include debt as well as lease liabilities.", "label": "Current Borrowings.", "negatedPeriodEndLabel": "Total current debt at end of period", "negatedPeriodStartLabel": "Total current debt at beginning of period" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "negatedLabel": "Interest-bearing loans and borrowings", "negatedPeriodEndLabel": "Interest-bearing loans and borrowings at end of period", "negatedPeriodStartLabel": "Interest-bearing loans and borrowings at beginning of period" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_CurrentDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current derivative financial assets", "verboseLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current derivative financial liabilities", "negatedLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r257" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current investments", "periodEndLabel": "Other investments - current at end of period", "periodStartLabel": "Other investments - current at beginning of period", "terseLabel": "Other investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current lease liabilities", "negatedPeriodEndLabel": "Current instalments of leases at end of period", "negatedPeriodStartLabel": "Current instalments of leases at beginning of period", "negatedTerseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "negatedTotalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r46", "r179", "r218" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPortionOfLongtermBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of non-current borrowings", "negatedPeriodEndLabel": "Current instalments of loans at end of period", "negatedPeriodStartLabel": "Current instalments of loans at beginning of period" } }, "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current provisions", "negatedLabel": "Provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r169" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Income tax receivable" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_CurrentTaxAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, non-current", "terseLabel": "Income tax receivable" } }, "en": { "role": { "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax liabilities, current", "negatedLabel": "Income tax payable" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_CurrentTaxLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax liabilities, non-current", "negatedLabel": "Income tax payable" } }, "en": { "role": { "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r170" ] }, "azn_DamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DamagesAwardedValue", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Damages awarded, value.", "label": "Damages awarded, value", "terseLabel": "Damages awarded, Value" } } }, "auth_ref": [] }, "azn_DamagesReceivedFromCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DamagesReceivedFromCounterparty", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Damages received from counterparty.", "label": "Damages received from counterparty" } } }, "auth_ref": [] }, "azn_DatrowayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DatrowayMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member represents Datroway.", "label": "Datroway [Member]", "terseLabel": "Datroway" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r122", "r171", "r175" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities", "negatedLabel": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r4", "r122", "r171", "r175" ] }, "azn_DefiniensCommercialLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DefiniensCommercialLitigationMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Definiens commercial litigation", "label": "Definiens commercial litigation [Member]", "terseLabel": "Definiens commercial litigation" } } }, "auth_ref": [] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Derivatives [member]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r219", "r220", "r227", "r231" ] }, "azn_DiabetesAllianceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DiabetesAllianceMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Diabetes Alliance.", "label": "Diabetes alliance", "terseLabel": "Diabetes alliance" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted earnings per $0.25 Ordinary Share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r9", "r10" ] }, "azn_DisclosureOfAllianceRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfAllianceRevenueTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenue" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of alliance revenue", "label": "Disclosure of alliance revenue [Text Block]", "terseLabel": "Alliance Revenue" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "verboseLabel": "Basis of preparation and accounting policies" } } }, "auth_ref": [ "r255" ] }, "ifrs-full_DisclosureOfBusinessCombinationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [line items]", "terseLabel": "Disclosure of detailed information about business combination" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBusinessCombinationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of business combinations." } } }, "auth_ref": [ "r70", "r138" ] }, "azn_DisclosureOfCollaborationRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfCollaborationRevenueTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenue" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of collaboration revenue", "label": "Disclosure of collaboration revenue [Text Block]", "terseLabel": "Collaboration Revenue" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "verboseLabel": "Legal proceedings and contingent liabilities" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r255" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r16", "r129" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails", "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Basis of preparation and accounting policies", "verboseLabel": "Net debt" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails", "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r254" ] }, "azn_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentHalfYearPeriodYearOnYearTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentHalfYearPeriodYearOnYearTableTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Tables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers, current half year period, year-on-year.", "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers, Current Half Year Period, Year On Year [Table Text Block]", "terseLabel": "Product Sales year-on-year analysis: H1 2026" } } }, "auth_ref": [] }, "azn_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentPeriodYearOnYearTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersCurrentPeriodYearOnYearTableTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Tables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers, current period, year-on-year.", "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers, Current Period, Year On Year [Table Text Block]", "terseLabel": "Product Sales year-on-year analysis: Q2 2026" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "verboseLabel": "Schedule of collaboration revenue" } } }, "auth_ref": [ "r58", "r107" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Revenues", "verboseLabel": "Product sales" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r58", "r107" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial Instruments" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r88" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r255" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r21", "r133" ] }, "azn_DisclosureOfNetDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfNetDebtTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebt" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of net debt.", "label": "Disclosure of Net Debt [Text Block]", "terseLabel": "Net debt" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpense" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income (expense) [text block]", "verboseLabel": "Other operating income and expense" } } }, "auth_ref": [ "r255" ] }, "azn_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpenseTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of other operating income or expense.", "label": "Disclosure of other operating income (expense) [table text block]", "terseLabel": "Schedule of other operating income and expense" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProductsAndServicesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesLineItems", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesTable", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the entity's products and services." } } }, "auth_ref": [ "r99" ] }, "azn_DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfRevenueProductSalesAnalysisCurrentPeriodTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for product sales analysis, current period, year-on-year.", "label": "Disclosure of Revenue Product Sales Analysis Current Period [Text Block]", "terseLabel": "Product Sales year-on-year analysis: Q2 2026" } } }, "auth_ref": [] }, "azn_DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DisclosureOfRevenueProductSalesYearToDateAnalysisTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of revenue product sales, year to date analysis", "label": "Disclosure of revenue product sales, year to date analysis [Text Block]", "terseLabel": "Product Sales year-on-year analysis: H1 2026" } } }, "auth_ref": [] }, "ifrs-full_DistributionCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DistributionCosts", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Distribution costs", "negatedLabel": "Distribution expense" } } }, "auth_ref": [ "r199", "r240" ] }, "ifrs-full_DividendsPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DividendsPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends paid, classified as financing activities", "negatedLabel": "Dividends paid" } }, "en": { "role": { "documentation": "The cash outflow for dividends paid by the entity, classified as financing activities." } } }, "auth_ref": [ "r31" ] }, "azn_DividendsRecognisedAsDistributionsToOwnersOfParentNetOfForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "DividendsRecognisedAsDistributionsToOwnersOfParentNetOfForfeiture", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount of dividends, net of forfeitures, recognised as distributions to owners of the parent.", "label": "Dividends recognised as distributions to owners of parent, net of forfeiture", "negatedLabel": "Dividends" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]", "terseLabel": "Earnings per share" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnCashAndInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents resulting from foreign exchange.", "label": "Effect of exchange rate changes, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents - Exchange movements" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange rate effects" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r29", "r30" ] }, "azn_EffectOfExchangeRateChangesOnCashAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnCashAndInvestments", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnNetFundsAndBorrowings", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in cash and investments resulting from foreign exchange.", "label": "Effect of exchange rate changes On Cash and Investments", "totalLabel": "Cash and investments - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnCurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnCurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowing", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in current borrowings and current portion of non-current borrowing resulting from foreign exchange.", "label": "Effect of exchange rate changes on Current borrowings and current portion of non-current borrowing", "negatedLabel": "Current borrowings and current portion of non-current borrowing - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnCurrentInstalmentsOfLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnCurrentInstalmentsOfLoans", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in current borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on current instalments of loans", "negatedLabel": "Current instalments of loans - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnCurrentLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnCurrentLeases", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in current leases resulting from foreign exchange.", "label": "Effect of exchange rate changes on current Leases", "negatedLabel": "Current instalments of leases - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnGrossBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnGrossBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnNetBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in gross borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on Gross Borrowings", "negatedTotalLabel": "Gross borrowings - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnNetBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnNetBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnNetFundsAndBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in net borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on Net Borrowings", "negatedTotalLabel": "Net borrowings - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnNetFundsAndBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnNetFundsAndBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in net funds and borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on Net Funds and Borrowings", "negatedTotalLabel": "Net debt - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnNonCurrentLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnNonCurrentLeases", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnTotalNonCurrentBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in non-current leases resulting from foreign exchange.", "label": "Effect of exchange rate changes on non-current Leases", "negatedLabel": "Non-current installments of leases - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnTotalCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnTotalCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnGrossBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in total current borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on total current Borrowings", "negatedLabel": "Total current debt - Exchange movements" } } }, "auth_ref": [] }, "azn_EffectOfExchangeRateChangesOnTotalNonCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EffectOfExchangeRateChangesOnTotalNonCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnGrossBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in total non-current borrowings resulting from foreign exchange.", "label": "Effect of exchange rate changes on total Non-current Borrowings", "negatedTotalLabel": "Total long-term debt - Exchange movements" } } }, "auth_ref": [] }, "azn_EmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EmergingMarketsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the information pertaining to Emerging Markets.", "label": "Emerging Markets", "terseLabel": "Emerging Markets" } } }, "auth_ref": [] }, "azn_EnhertuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EnhertuMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Enhertu.", "label": "Enhertu", "terseLabel": "Enhertu" } } }, "auth_ref": [] }, "azn_EnhertuPatentProceedingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EnhertuPatentProceedingsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Enhertu patent proceedings", "label": "Enhertu patent proceedings [Member]", "terseLabel": "Enhertu patent proceedings" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r247" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Equity at end of period", "periodStartLabel": "Equity at beginning of period", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r37", "r39", "r54", "r55", "r56", "r124", "r136", "r149", "r150", "r153", "r174", "r182" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Capital and reserves attributable to equity holders of the Parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r173" ] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent [member]", "terseLabel": "Total attributable to owners of the parent" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_EquityInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityInvestmentsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity investments [member]", "terseLabel": "Equity investments" } }, "en": { "role": { "documentation": "This member stands for investments in equity instruments." } } }, "auth_ref": [ "r227", "r231" ] }, "azn_EstablishedRowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EstablishedRowMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "The member stands for established ROW.", "label": "Established ROW", "terseLabel": "Established RoW" } } }, "auth_ref": [] }, "azn_EtcamahMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "EtcamahMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Etcamah.", "label": "Etcamah [Member]", "terseLabel": "Etcamah" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EuropeMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "FRANCE" } } }, "auth_ref": [] }, "azn_FarxigaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FarxigaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Farxiga.", "label": "Farxiga", "terseLabel": "Farxiga" } } }, "auth_ref": [] }, "azn_FarxigaSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FarxigaSalesMilestonesMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Farxiga, sales milestones", "label": "Farxiga, sales milestones [Member]", "terseLabel": "Farxiga: sales milestones" } } }, "auth_ref": [] }, "azn_FasenraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FasenraMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Fasenra.", "label": "Fasenra", "terseLabel": "Fasenra" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Finance expense" } } }, "auth_ref": [ "r192" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance income" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r145", "r146", "r147", "r226" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at amortised cost, category [member]", "terseLabel": "Financial assets at amortised cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r85", "r140" ] }, "ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets designated as measured at fair value through profit or loss [abstract]", "terseLabel": "Financial instruments fair value gains" } } }, "auth_ref": [] }, "azn_FinancialAssetsMeasuredAtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FinancialAssetsMeasuredAtFairValueMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents financial assets measured at fair value", "label": "Financial assets measured at fair value [Member]", "terseLabel": "Financial assets measured at fair value" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets pledged as collateral for liabilities or contingent liabilities", "terseLabel": "Cash collateral pledged to counterparties" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Classes of contingent liabilities [domain]; Financial assets]" } } }, "auth_ref": [ "r75", "r142" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "verboseLabel": "Carrying value, financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r78" ] }, "azn_FinancialResourcesThatIncludeCashUndrawnCommittedBankFacilitiesExcludingCurrentOutstandingDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FinancialResourcesThatIncludeCashUndrawnCommittedBankFacilitiesExcludingCurrentOutstandingDebt", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of financial resources that include cash, undrawn committed bank facilities less outstanding debt due within one year.", "label": "Financial resources that include cash, undrawn committed bank facilities excluding current outstanding debt", "terseLabel": "Financial resources" } } }, "auth_ref": [] }, "azn_FlumistMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "FlumistMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for FluMist.", "label": "FluMist", "terseLabel": "FluMist" } } }, "auth_ref": [] }, "azn_ForxigaPatentProceedingsAustraliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ForxigaPatentProceedingsAustraliaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Forxiga patent proceedings in Australia.", "label": "Forxiga patent proceedings, Australia [member]", "terseLabel": "Forxiga patent proceedings, Australia" } } }, "auth_ref": [] }, "azn_ForxigaPatentProceedingsEuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ForxigaPatentProceedingsEuropeMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Forxiga patent proceedings in Europe.", "label": "Forxiga patent proceedings, Europe [member]", "terseLabel": "Forxiga patent proceedings, Europe" } } }, "auth_ref": [] }, "azn_GainsCostsOfHedgingBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "GainsCostsOfHedgingBeforeTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The amount of gains (cost) of hedging.", "label": "Gains (costs) of hedging before tax", "terseLabel": "Gains of hedging" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnCashFlowHedgesBeforeTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gains (losses) on cash flow hedges, before tax", "terseLabel": "Fair value movements on cash flow hedges" } }, "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]" } } }, "auth_ref": [ "r196" ] }, "azn_GainsLossesOnExchangeDifferenceHedgesOfNetInvestmentsInForeignOperationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "GainsLossesOnExchangeDifferenceHedgesOfNetInvestmentsInForeignOperationsBeforeTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange difference hedges of net investments in foreign operations, before tax.", "label": "Gains (losses) on exchange difference hedges of net investments in foreign operations, before tax", "terseLabel": "Foreign exchange arising on designated liabilities in net investment hedges" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101", "r200", "r222", "r225", "r235" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r101", "r200", "r222", "r225", "r235" ] }, "azn_GoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "GoingConcernAbstract", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "na", "label": "Going Concern [Abstract]", "terseLabel": "Going concern" } } }, "auth_ref": [] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r13", "r15", "r72", "r126", "r128", "r139", "r163" ] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "Gross profit" } } }, "auth_ref": [ "r240" ] }, "azn_HedgeContractsRelatingToDividendPaymentsReceiptsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "HedgeContractsRelatingToDividendPaymentsReceiptsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow or outflow from hedge contracts relating to dividend payments (receipts).", "label": "Hedge contracts relating to dividend payments (receipts) , classified as financing activities", "negatedLabel": "Hedge contracts relating to dividend payments" } } }, "auth_ref": [] }, "azn_IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IfrsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPolicies" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts.", "label": "Ifrs Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of preparation and accounting policies" } } }, "auth_ref": [] }, "azn_IfrsCommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IfrsCommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Legal proceedings and contingent liabilities" } } }, "auth_ref": [] }, "azn_IfrsMoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IfrsMoneyMarketFundsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for money market funds.", "label": "Money market funds", "terseLabel": "Money market funds" } } }, "auth_ref": [] }, "azn_ImfinziMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ImfinziMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Imfinzi.", "label": "Imfinzi", "terseLabel": "Imfinzi" } } }, "auth_ref": [] }, "azn_ImjudoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ImjudoMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Imjudo", "label": "Imjudo [Member]", "terseLabel": "Imjudo" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } } }, "auth_ref": [ "r19", "r131" ] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Taxation" } } }, "auth_ref": [ "r1", "r2", "r3", "r8", "r52", "r91", "r119", "r120", "r121", "r194" ] }, "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss", "negatedLabel": "Tax income/(expense) on items that may be reclassified subsequently to profit and loss" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss", "negatedLabel": "Tax expense on items that will not be reclassified to profit or loss" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax paid" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r32", "r204" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net (decrease)/increase in Cash and cash equivalents in the period" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r35", "r117" ] }, "azn_IncreaseDecreaseInNetDebtPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseInNetDebtPosition", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in the net debt position.", "label": "Increase Decrease in Net Debt Position", "verboseLabel": "Increase (decrease) in net debt" } } }, "auth_ref": [] }, "azn_IncreaseDecreaseInRevenueConstantExchangeRateYearOnYearAsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseInRevenueConstantExchangeRateYearOnYearAsPercentage", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) in revenue based on constant exchange rate, year-on-year, as a percent.", "label": "Increase (Decrease) in Revenue, Constant Exchange Rate, Year On Year, as a Percentage", "terseLabel": "CER %, year-on-year" } } }, "auth_ref": [] }, "azn_IncreaseDecreaseInRevenueYearOnYearPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseInRevenueYearOnYearPercentage", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the actual increase (decrease) in revenue, year-on-year, as a percent.", "label": "Increase (Decrease) In Revenue, Year On Year, Percentage", "terseLabel": "Actual %, year-on-year" } } }, "auth_ref": [] }, "azn_IncreaseDecreaseInWorkingCapitalAndShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseInWorkingCapitalAndShortTermProvisions", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in working capital and short-term provisions.", "label": "Increase (decrease) in working capital and Short Term Provisions", "negatedLabel": "Movement in working capital and short-term provisions" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity", "terseLabel": "Changes in non-controlling interests" } }, "en": { "role": { "documentation": "The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r159" ] }, "azn_IncreaseDecreaseThroughForeignExchangeNonCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseThroughForeignExchangeNonCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_EffectOfExchangeRateChangesOnTotalNonCurrentBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in non-current borrowings resulting from foreign exchange.", "label": "Increase (decrease) through foreign exchange, Non-current Borrowings", "negatedLabel": "Non-current installments of loans - Exchange movements" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payments charge for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r159" ] }, "azn_IncreaseDecreaseThroughTransferBetweenOtherReservesAndRetainedEarningsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IncreaseDecreaseThroughTransferBetweenOtherReservesAndRetainedEarningsEquity", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from transfers between the other reserves and retained earnings.", "label": "Increase (decrease) through transfer between other reserves and retained earnings, equity", "terseLabel": "Transfer to Other reserves" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Movement in shares held by Employee Benefit Trusts" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r160" ] }, "azn_InfectiousDiseaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "InfectiousDiseaseMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member represents Infectious Disease.", "label": "Infectious Disease [Member]", "terseLabel": "ID" } } }, "auth_ref": [] }, "azn_InfectiousDiseaseOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "InfectiousDiseaseOtherMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member represents Infectious Disease, other.", "label": "Infectious Disease, other [member]", "terseLabel": "Other ID" } } }, "auth_ref": [] }, "azn_IntangibleAssetsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IntangibleAssetsClassifiedAsCurrent", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Intangible assets, classified as current", "label": "Intangible assets, classified as current", "verboseLabel": "Intangible assets" } } }, "auth_ref": [] }, "azn_IntangibleAssetsFromCollaborationAndLicenseAgreementWithCspcPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "IntangibleAssetsFromCollaborationAndLicenseAgreementWithCspcPharmaceuticalsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents intangible assets from the collaboration and license agreement with CSPC Pharmaceuticals.", "label": "Intangible assets from collaboration and license agreement with CSPC Pharmaceuticals [member]", "terseLabel": "Intangible assets from collaboration and license agreement with CSPC Pharmaceuticals" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r20", "r132", "r163" ] }, "ifrs-full_IntangibleAssetsUnderDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsUnderDevelopmentMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets under development [member]", "terseLabel": "Products in development" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r203" ] }, "azn_InterestBearingLoansAndBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "InterestBearingLoansAndBorrowingsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for interest-bearing loans and borrowings.", "label": "Interest-Bearing Loans and Borrowings", "terseLabel": "Interest-Bearing Loans and Borrowings" } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedLabel": "Interest paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received, classified as investing activities", "terseLabel": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r7", "r116", "r165", "r242" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "terseLabel": "Investments in associates and joint ventures" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r53", "r93", "r148", "r164" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of Ordinary Shares" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r238", "r244" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r161" ] }, "azn_KoselugoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "KoselugoMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Koselugo.", "label": "Koselugo", "terseLabel": "Koselugo" } } }, "auth_ref": [] }, "azn_LegalProceedingsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "LegalProceedingsPolicyTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to legal proceedings.", "label": "Legal Proceedings [Policy Text Block]", "terseLabel": "Legal proceedings" } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r12", "r14", "r55", "r127", "r150" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r55", "r150" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r6", "r55", "r150" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "negatedTotalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r54", "r55", "r56", "r92", "r97", "r149", "r150", "r174" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities [abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "azn_LitigationSettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "LitigationSettlementAmount", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of consideration paid, payable, or recognized to settle litigation or other legal disputes..", "label": "Litigation Settlement Amount", "terseLabel": "Litigation settlement amount" } } }, "auth_ref": [] }, "azn_LokelmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "LokelmaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lokelma.", "label": "Lokelma", "terseLabel": "Lokelma" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "negatedLabel": "Interest-bearing loans and borrowings", "negatedPeriodEndLabel": "Non-current installments of loans at end of period", "negatedPeriodStartLabel": "Non-current installments of loans at beginning of period" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term borrowings [member]", "terseLabel": "Long-term loans" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r213", "r216" ] }, "azn_LynparzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "LynparzaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lynparza.", "label": "Lynparza", "terseLabel": "Lynparza" } } }, "auth_ref": [] }, "ifrs-full_MarketsOfCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MarketsOfCustomersAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Markets of customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r223", "r236" ] }, "ifrs-full_MarketsOfCustomersDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MarketsOfCustomersDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Markets of customers [domain]" } }, "en": { "role": { "documentation": "This member stands for all markets of customers. It also represents the standard value for the 'Markets of customers' axis if no other member is used." } } }, "auth_ref": [ "r223", "r236" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59", "r63", "r64", "r65", "r66", "r67", "r68", "r77", "r82", "r106", "r108", "r111", "r113", "r144", "r177", "r201", "r228" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r59", "r63", "r64", "r65", "r66", "r67", "r68", "r77", "r106", "r108", "r111", "r113", "r144", "r177", "r201", "r228", "r229" ] }, "azn_MaximumPayablesForRegulatoryMilestonesUnderCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "MaximumPayablesForRegulatoryMilestonesUnderCollaborationAgreement", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum payables for regulatory milestones under collaboration agreement.", "label": "Maximum payables for regulatory milestones under collaboration agreement" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r25", "r26", "r54", "r135", "r149" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r25", "r26", "r54", "r135", "r149" ] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets (liabilities)", "totalLabel": "Net assets" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r217", "r256" ] }, "azn_NetBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NetBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of total borrowings less net derivative financial instruments.", "label": "Net Borrowings", "negatedPeriodEndLabel": "Net borrowings at end of period", "negatedPeriodStartLabel": "Net borrowings at beginning of period" } } }, "auth_ref": [] }, "ifrs-full_NetDebt": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDebt", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "label": "Net debt", "negatedPeriodEndLabel": "Net debt at end of period", "negatedPeriodStartLabel": "Net debt at beginning of period" } }, "en": { "role": { "documentation": "The amount of net debt of the entity." } } }, "auth_ref": [ "r256" ] }, "azn_NetDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NetDebtAbstract", "lang": { "en-us": { "role": { "documentation": "na", "label": "Net debt." } } }, "auth_ref": [] }, "azn_NetDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NetDerivativeFinancialInstruments", "crdr": "debit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Net derivative financial instruments", "label": "Net derivative financial instruments", "periodEndLabel": "Net derivative financial instruments at end of period", "periodStartLabel": "Net derivative financial instruments at beginning of period" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsCurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, current Borrowings", "negatedLabel": "Current instalments of loans - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsCurrentLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsCurrentLeases", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current leases due to non-cash and other movements.", "label": "Non-cash and Other Movements, current Leases", "negatedLabel": "Current instalments of leases - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsGrossBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsGrossBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsNetBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in gross borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Gross Borrowings", "negatedTotalLabel": "Gross borrowings - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsNetBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsNetBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsNetFundsAndBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Net Borrowings", "negatedTotalLabel": "Net borrowings - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsNetDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsNetDerivativeFinancialInstruments", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsNetBorrowings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net derivative financial instruments due to non-cash and other movements.", "label": "Non-cash and Other Movements, Net Derivative financial instruments", "terseLabel": "Net derivative financial instruments - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsNetFundsAndBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsNetFundsAndBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net funds and borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Net Funds and Borrowings", "negatedTotalLabel": "Net debt - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsNonCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsNonCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsTotalNonCurrentBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in non-current borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Non-current Borrowings", "negatedLabel": "Non-current installments of loans - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsNonCurrentLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsNonCurrentLeases", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsTotalNonCurrentBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in non-current leases due to non-cash and other movements.", "label": "Non-cash and Other Movements, Non-current Leases", "negatedLabel": "Non-current installments of leases - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsTotalCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsTotalCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsGrossBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in total current borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Total current Borrowings", "negatedLabel": "Total current debt - Non-cash & other" } } }, "auth_ref": [] }, "azn_NonCashAndOtherMovementsTotalNonCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NonCashAndOtherMovementsTotalNonCurrentBorrowings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/DisclosureNetDebtDetailsCalc2": { "parentTag": "azn_NonCashAndOtherMovementsGrossBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in total non-current borrowings due to non-cash and other movements.", "label": "Non-cash and Other Movements, Total Non-current Borrowings", "negatedTotalLabel": "Total long-term debt - Non-cash & other" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r118" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r118" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r41", "r43", "r172" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests [member]", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r45", "r178", "r218" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "azn_NoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-current borrowings which may include debt as well as lease liabilities.", "label": "Noncurrent Borrowings", "negatedPeriodEndLabel": "Total long-term debt at end of period", "negatedPeriodStartLabel": "Total long-term debt at beginning of period" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial assets", "verboseLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "negatedLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current investments other than investments accounted for using equity method", "terseLabel": "Other investments" } }, "en": { "role": { "documentation": "The amount of non-current investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "negatedPeriodEndLabel": "Non-current installments of leases at end of period", "negatedPeriodStartLabel": "Non-current installments of leases at beginning of period", "negatedTerseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "negatedTotalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r47", "r179", "r218" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPayables", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other non-current payables", "negatedLabel": "Other payables" } }, "en": { "role": { "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]" } } }, "auth_ref": [ "r168" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions", "negatedLabel": "Provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r169" ] }, "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current net defined benefit liability", "negatedLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Due within one year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r63", "r64", "r68", "r110", "r112", "r176", "r228", "r230" ] }, "ifrs-full_NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Not measured at fair value in statement of financial position but for which fair value is disclosed [member]", "terseLabel": "Not measured at fair value in statement of financial position but for which fair value is disclosed" } }, "en": { "role": { "documentation": "This member stands for items not measured at fair value in the statement of financial position but for which fair value is disclosed. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r57" ] }, "azn_NumberOfAppealsPriorToDismissal": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfAppealsPriorToDismissal", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of appeals prior to dismissal.", "label": "Number of appeals prior to dismissal" } } }, "auth_ref": [] }, "azn_NumberOfPatentTrialsConcluded": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfPatentTrialsConcluded", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patent trials concluded.", "label": "Number Of Patent Trials Concluded", "terseLabel": "Number of patent trials concluded" } } }, "auth_ref": [] }, "azn_NumberOfPatentsBeingChallenged": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfPatentsBeingChallenged", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patents being challenged.", "label": "Number of patents being challenged", "terseLabel": "Number of patents being challenged" } } }, "auth_ref": [] }, "azn_NumberOfPatentsClaimedToBeInfringed": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfPatentsClaimedToBeInfringed", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patents claimed to be infringed.", "label": "Number of patents claimed to be infringed" } } }, "auth_ref": [] }, "azn_NumberOfPatentsInvalidated": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfPatentsInvalidated", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patents invalidated.", "label": "Number of Patents Invalidated", "terseLabel": "Number of patents invalidated" } } }, "auth_ref": [] }, "azn_NumberOfProceedingsInWhichCounterpartyHasDisclaimedAllPatents": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfProceedingsInWhichCounterpartyHasDisclaimedAllPatents", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of proceedings in which counterparty has disclaimed all patents", "label": "Number of proceedings in which counterparty has disclaimed all patents", "terseLabel": "Number of proceedings in which counterparty has disclaimed all patents" } } }, "auth_ref": [] }, "azn_NumberOfProgrammesInitiallyProgressedUnderCollaborationAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfProgrammesInitiallyProgressedUnderCollaborationAgreement", "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of programmes initially progressed under collaboration agreement.", "label": "Number of programmes initially progressed under collaboration agreement" } } }, "auth_ref": [] }, "azn_NumberOfRoyaltyBearingPatentLicenseAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "NumberOfRoyaltyBearingPatentLicenseAgreements", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of royalty-bearing patent license agreements.", "label": "Number of Royalty Bearing Patent License Agreements", "terseLabel": "Number of royalty-bearing patent license agreements" } } }, "auth_ref": [] }, "azn_OncologyProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OncologyProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for oncology products.", "label": "Total Oncology", "terseLabel": "Total Oncology" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Non-cash and other movements" } } }, "auth_ref": [ "r251" ] }, "azn_OtherAllianceRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherAllianceRevenueMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other alliance revenue", "label": "Other alliance revenue [Member]", "terseLabel": "Other Alliance Revenue" } } }, "auth_ref": [] }, "azn_OtherCardiovascularRenalAndMetabolismProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherCardiovascularRenalAndMetabolismProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other cardiovascular, renal and metabolism products.", "label": "CVRM, Others", "terseLabel": "Other CVRM" } } }, "auth_ref": [] }, "azn_OtherCollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherCollaborationRevenueMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other collaboration revenue.", "label": "Other Collaboration Revenue", "terseLabel": "Other Collaboration Revenue" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive income, for the period, net of tax", "verboseLabel": "Other comprehensive income (expense)" } } }, "auth_ref": [ "r50", "r158", "r185", "r195" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income:" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, before tax, exchange differences on translation of foreign operations", "terseLabel": "Foreign exchange arising on consolidation" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]" } } }, "auth_ref": [ "r180", "r196" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, before tax, gains (losses) from investments in equity instruments", "verboseLabel": "Net gains/(losses) on equity investments measured at fair value through Other comprehensive income" } } }, "auth_ref": [ "r76", "r143", "r180", "r196" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of the defined benefit pension liability" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r180", "r196", "r248" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, before tax, hedges of net investments in foreign operations", "verboseLabel": "Fair value movements on derivatives designated in net investment hedges" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income, before tax]" } } }, "auth_ref": [ "r24", "r103", "r196" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Total other comprehensive income that may be reclassified subsequently to profit and loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r245", "r246" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Total other comprehensive income that will not be reclassified to profit and loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r245", "r246" ] }, "azn_OtherFinancialAssetInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherFinancialAssetInvestmentMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other financial asset investments.", "label": "Other Investments" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "terseLabel": "Movement in short-term investments, fixed deposits and other investing instruments" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r28" ] }, "azn_OtherLoansCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherLoansCommercialPaperMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for commercial paper.", "label": "Commercial paper" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentReceivables", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of non-current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r237", "r243" ] }, "azn_OtherOncologyProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherOncologyProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other oncology products.", "label": "Oncology, Others", "terseLabel": "Other Oncology" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureOtherOperatingIncomeAndExpenseDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income and expense", "verboseLabel": "Total other operating income and expense" } } }, "auth_ref": [ "r258" ] }, "azn_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other products.", "label": "Total Other medicines", "terseLabel": "Total Other medicines" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r238", "r244" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Other reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r115", "r161" ] }, "azn_OtherRespiratoryProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherRespiratoryProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other respiratory and immunology products.", "label": "Respiratory, Others", "terseLabel": "Other R&I" } } }, "auth_ref": [] }, "azn_OtherRoyaltyIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherRoyaltyIncomeMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents other royalty income not separately disclosed in the same statement or note.", "label": "Other royalty income [Member]", "terseLabel": "Other royalty income" } } }, "auth_ref": [] }, "azn_OtherShortTermBorrowingsExcludingOverdraftsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "OtherShortTermBorrowingsExcludingOverdraftsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other short-term borrowings excluding overdrafts.", "label": "Other short-term borrowings excluding overdrafts" } } }, "auth_ref": [] }, "country_PL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "PL", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "POLAND" } } }, "auth_ref": [] }, "country_PT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "PT", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "label": "PORTUGAL" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value per ordinary share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r114", "r151", "r183" ] }, "azn_ParpInhibitorRoyaltyDisputeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ParpInhibitorRoyaltyDisputeMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the PARP Inhibitor Royalty Dispute.", "label": "PARP Inhibitor Royalty Dispute" } } }, "auth_ref": [] }, "ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsFromChangesInOwnershipInterestsInSubsidiaries", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments from changes in ownership interests in subsidiaries that do not result in loss of control", "negatedLabel": "Payments to acquire non-controlling interests" } }, "en": { "role": { "documentation": "The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r33", "r34" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of obligations under leases" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsToAcquireOrRedeemEntitysShares", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to acquire or redeem entity's shares", "negatedTerseLabel": "Own shares purchased by Employee Benefit Trusts" } }, "en": { "role": { "documentation": "The cash outflow to acquire or redeem entity's shares." } } }, "auth_ref": [ "r208" ] }, "azn_PercentageOfRoyaltiesOnSalesToPayToCounterparty": { "xbrltype": "percentItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "PercentageOfRoyaltiesOnSalesToPayToCounterparty", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties on sales to pay to counterparty", "label": "Percentage of royalties on sales to pay to counterparty", "terseLabel": "Percentage of royalties on sales to pay to counterparty" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "verboseLabel": "Issue of loans and borrowings" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from issue of share capital" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r207" ] }, "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of other long-term assets, classified as investing activities", "terseLabel": "Disposal of non-current asset investments" } }, "en": { "role": { "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of intangible assets, classified as investing activities", "verboseLabel": "Disposal of intangible assets" } }, "en": { "role": { "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "terseLabel": "Disposal of property, plant and equipment" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r206" ] }, "azn_ProductRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ProductRevenue", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The amount of revenue arising from the sale of goods and alliance revenue.", "label": "Product revenue", "totalLabel": "Product Revenue" } } }, "auth_ref": [] }, "azn_ProductSalesAnalysisCurrentPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ProductSalesAnalysisCurrentPeriodAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Product Sales year-on-year analysis: Q2 2026" } } }, "auth_ref": [] }, "azn_ProductSalesYearToDateAnalysisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ProductSalesYearToDateAnalysisAbstract", "lang": { "en-us": { "role": { "documentation": "Product sales, year to date analysis", "label": "Product Sales year-on-year analysis: H1 2026" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r99", "r221", "r234" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureCollaborationRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r99", "r221", "r234" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 1.0 }, "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Profit for the period", "totalLabel": "Profit for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r38", "r40", "r92", "r95", "r125", "r137", "r157", "r184", "r218", "r224" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAbstract", "lang": { "en-us": { "role": { "label": "Other operating income and expense" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to [abstract]", "terseLabel": "Profit/(loss) attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r42", "r187" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeCalc2": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Owners of the Parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Profit before tax", "verboseLabel": "Profit before tax" } } }, "auth_ref": [ "r74", "r232", "r233", "r239", "r240" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit" } } }, "auth_ref": [ "r202", "r258" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "netLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r5", "r123", "r162" ] }, "azn_PulmicortMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "PulmicortMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pulmicort.", "label": "Pulmicort", "terseLabel": "Pulmicort" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureIntangibleAssetsDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Purchase of intangible assets" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of interests in investments accounted for using equity method", "negatedLabel": "Payments to associates and joint ventures" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of other long-term assets, classified as investing activities", "negatedLabel": "Purchase of non-current asset investments" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property, plant and equipment" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r205" ] }, "azn_RareDiseaseOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RareDiseaseOtherMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member represents Rare Disease, other.", "label": "Rare Disease, other [Member]", "terseLabel": "Other Rare Disease" } } }, "auth_ref": [] }, "azn_RareDiseasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RareDiseasesMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Rare diseases", "label": "Total rare diseases", "terseLabel": "Total rare diseases" } } }, "auth_ref": [] }, "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Reclassification adjustments on cash flow hedges, before tax", "negatedLabel": "Fair value movements on cash flow hedges transferred to profit and loss" } }, "en": { "role": { "documentation": "The amount of reclassification adjustments related to cash flow hedges, before tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]" } } }, "auth_ref": [ "r198" ] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtDetails", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of loans and borrowings", "terseLabel": "Repayment of loans and borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r210" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expense" } } }, "auth_ref": [ "r22", "r134" ] }, "azn_RespiratoryProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RespiratoryProductsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for respiratory and immunology products.", "label": "BioPharmaceuticals: total Respiratory & Immunology", "terseLabel": "BioPharmaceuticals: total Respiratory & Immunology" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r238", "r244", "r246" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Retained earnings" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r161", "r241" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue", "totalLabel": "Total Revenue" } } }, "auth_ref": [ "r49", "r74", "r89", "r94", "r99", "r100", "r102", "r191", "r218", "r239", "r240" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "lang": { "en-us": { "role": { "label": "Collaboration Revenue." } } }, "auth_ref": [] }, "ifrs-full_RevenueFromSaleOfGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromSaleOfGoods", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "azn_ProductRevenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details", "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue from sale of goods", "terseLabel": "Product Sales" } } }, "auth_ref": [ "r256" ] }, "azn_RevenueFromSaleOfGoodsNetOfReversals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RevenueFromSaleOfGoodsNetOfReversals", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of goods net of reversals", "label": "Revenue from sale of goods net of reversals", "terseLabel": "Product sales net of reversals" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r60", "r62", "r109" ] }, "azn_RoxadustatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RoxadustatMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Roxadustat.", "label": "roxadustat", "terseLabel": "roxadustat" } } }, "auth_ref": [] }, "azn_RussianMinistryOfHealthMohMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "RussianMinistryOfHealthMohMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Russian Ministry of Health (MOH).", "label": "Russian Ministry of Health (MOH) [Member]", "terseLabel": "Russian Ministry of Health (MOH)" } } }, "auth_ref": [] }, "azn_SaphneloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SaphneloMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Saphnelo", "label": "Saphnelo", "terseLabel": "Saphnelo" } } }, "auth_ref": [] }, "azn_ScheduleOfAllianceRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ScheduleOfAllianceRevenueTableTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of alliance revenue", "label": "Schedule of alliance revenue [Table Text Block]", "terseLabel": "Schedule of alliance revenue" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expense", "negatedLabel": "Selling, general and administrative expense" } } }, "auth_ref": [ "r258" ] }, "azn_SelokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SelokenMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Seloken.", "label": "Seloken [Member]", "terseLabel": "Seloken" } } }, "auth_ref": [] }, "azn_SettlementOfSharePlanAwardsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SettlementOfSharePlanAwardsEquity", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityCalc": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from settlement of share plan awards.", "label": "Settlement of share plan awards, Equity", "terseLabel": "Settlement of share plan awards" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method", "terseLabel": "Share of after tax losses in associates and joint ventures" } } }, "auth_ref": [ "r90", "r98", "r193" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Share premium account" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r238", "r244" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Share premium account" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r161" ] }, "azn_SolirisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SolirisMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Soliris", "label": "Soliris", "terseLabel": "Soliris" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed consolidated statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed consolidated statement of changes in equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Condensed consolidated statement of changes in equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Condensed consolidated statement of comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "azn_StrensiqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "StrensiqMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Strensiq", "label": "Strensiq", "terseLabel": "Strensiq" } } }, "auth_ref": [] }, "azn_SymbicortMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SymbicortMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Symbicort.", "label": "Symbicort", "terseLabel": "Symbicort" } } }, "auth_ref": [] }, "azn_SyntimmuneMilestoneLitigationUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "SyntimmuneMilestoneLitigationUsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Syntimmune Milestone Litigation in the US.", "label": "Syntimmune Milestone Litigation, US [Member]", "terseLabel": "Syntimmune Milestone Litigation, US" } } }, "auth_ref": [] }, "azn_TabularDisclosureOfNetDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TabularDisclosureOfNetDebtTableTextBlock", "presentation": [ "http://www.astrazeneca.com/role/DisclosureNetDebtTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of net debt.", "label": "Tabular Disclosure of Net Debt [Table Text Block]", "terseLabel": "Schedule of Net debt" } } }, "auth_ref": [] }, "azn_TagrissoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TagrissoMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Tagrisso.", "label": "Tagrisso", "terseLabel": "Tagrisso" } } }, "auth_ref": [] }, "azn_TagrissoPatentProceedingsRussiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TagrissoPatentProceedingsRussiaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Tagrisso Patent Proceedings in Russia.", "label": "Tagrisso Patent Proceedings, Russia [Member]", "terseLabel": "Tagrisso Patent Proceedings, Russia" } } }, "auth_ref": [] }, "azn_TagrissoUsPatentProceedingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TagrissoUsPatentProceedingsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Tagrisso US patent proceedings.", "label": "Tagrisso US patent proceedings [Member]", "terseLabel": "Tagrisso US patent proceedings" } } }, "auth_ref": [] }, "azn_TezspireMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TezspireMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureAllianceRevenueDetails", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Tezspire.", "label": "Tezspire", "terseLabel": "Tezspire" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "negatedLabel": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r168" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r152", "r166", "r181" ] }, "azn_TrialForForxigaPatentProceedingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TrialForForxigaPatentProceedingsMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trial related to Forxiga patent proceedings.", "label": "Trial For Forxiga Patent Proceedings [Member]", "terseLabel": "Trial for forxiga patent proceedings" } } }, "auth_ref": [] }, "azn_TruqapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "TruqapMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Truqap", "label": "Truqap [Member]", "terseLabel": "Truqap" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US" } } }, "auth_ref": [] }, "azn_UltomirisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "UltomirisMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "Ultomiris", "label": "Ultomiris", "terseLabel": "Ultomiris" } } }, "auth_ref": [] }, "ifrs-full_UndrawnBorrowingFacilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UndrawnBorrowingFacilities", "crdr": "credit", "presentation": [ "http://www.astrazeneca.com/role/DisclosureBasisOfPreparationAndAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Undrawn borrowing facilities", "terseLabel": "Undrawn committed bank facilities" } }, "en": { "role": { "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]" } } }, "auth_ref": [ "r214" ] }, "azn_UniversityOfSheffieldContractDisputeUkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "UniversityOfSheffieldContractDisputeUkMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureLegalProceedingsAndContingentLiabilitiesLegalProceedingsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for University Of Sheffield Contract Dispute, UK.", "label": "University Of Sheffield Contract Dispute, UK [Member]", "terseLabel": "University of Sheffield Contract Dispute, UK" } } }, "auth_ref": [] }, "azn_VaccineAndInfectionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "VaccineAndInfectionMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for vaccine and infection.", "label": "BioPharmaceuticals: Total V&I", "terseLabel": "BioPharmaceuticals: Total V&I" } } }, "auth_ref": [] }, "azn_WainuaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "WainuaMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Wainua", "label": "Wainua [Member]", "terseLabel": "Wainua" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.astrazeneca.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of Ordinary Shares in issue (millions)" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r11" ] }, "azn_ZoladexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.astrazeneca.com/20260630", "localname": "ZoladexMember", "presentation": [ "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisH12026Details", "http://www.astrazeneca.com/role/DisclosureProductSalesYearOnYearAnalysisQ22026Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Zoladex.", "label": "Zoladex", "terseLabel": "Zoladex" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_88&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "39", "IssueDate": "2025-01-01", "Paragraph": "102", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2025-en-r&anchor=para_102_a&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42A&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42B&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_g&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "6.5.13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_6.5.13_a&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_c&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "92", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_92&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_a&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_c&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }